BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2041832)

  • 1. Newer beta-lactam agents and the Bacteroides fragilis group.
    Cuchural GJ
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.
    Cuchural GJ; Snydman DR; McDermott L; Iannini PB; Hill GB; Cleary TJ; O'Keefe JP; Pierson CL; Rihs JD; Finegold SM
    Clin Ther; 1992; 14(1):122-36. PubMed ID: 1576621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the activity of imipenem and beta-lactams combined with sulbactam and clavulanic acid in beta-lactamase-producing strains of Bacteroides fragilis.
    Martín MA; Castillo AM; Liébana J; Marín A; Alados JC; Piédrola G
    J Hyg Epidemiol Microbiol Immunol; 1991; 35(2):189-97. PubMed ID: 1940333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
    Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM
    J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.
    Cuchural GJ; Tally FP; Jacobus NV; Cleary T; Finegold SM; Hill G; Iannini P; O'Keefe JP; Pierson C
    Antimicrob Agents Chemother; 1990 Mar; 34(3):479-80. PubMed ID: 2334161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro anaerobic data on ticarcillin/clavulanate. A review of an ongoing survey.
    Sanders CV; Aldridge KE
    J Reprod Med; 1990 Mar; 35(3 Suppl):313-6. PubMed ID: 2319513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group.
    Bourgault AM; Lamothe F
    J Antimicrob Chemother; 1986 May; 17(5):593-603. PubMed ID: 3636324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of 36 antimicrobial agents against clinically isolated Bacteroides fragilis.
    Teng LJ; Ho SW; Chang SC; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Aug; 90(8):796-9. PubMed ID: 1683376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
    Aldridge KE; Henderberg A; Sanders CV
    J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey of Bacteroides fragilis group susceptibility patterns in Canada.
    Bourgault AM; Lamothe F; Hoban DJ; Dalton MT; Kibsey PC; Harding G; Smith JA; Low DE; Gilbert H
    Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
    Appelbaum PC; Spangler SK; Jacobs MR
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1214-8. PubMed ID: 1929264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.
    Downes J; Andrew JH
    Pathology; 1988 Jul; 20(3):260-3. PubMed ID: 3205597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibilities of anaerobic gram-negative bacilli to thirteen antimicrobials and beta-lactamase inhibitor combinations.
    Hill GB; Ayers OM; Everett BQ
    J Antimicrob Chemother; 1991 Dec; 28(6):855-67. PubMed ID: 1816182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of beta-lactamase-inhibitor combinations.
    Fuchs PC; Barry AL
    J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of beta-lactamases in the Bacteroides fragilis group].
    Martin C; Dubreuil L; Sedallian A; Romond C
    Pathol Biol (Paris); 1990 May; 38(5):470-3. PubMed ID: 2367153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units.
    Gill CJ; Ponticas S; Shungu DL; Guerriero S
    Clin Ther; 1991; 13(1):25-37. PubMed ID: 2029725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
    Jacobs MR; Spangler SK; Appelbaum PC
    J Antimicrob Chemother; 1990 Sep; 26(3):361-70. PubMed ID: 2228827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The sensitivity of anaerobic bacteria to chemotherapeutic agents (Zurich, 1991)].
    Wüst J; Hardegger U
    Schweiz Rundsch Med Prax; 1991 Dec; 80(52):1474-80. PubMed ID: 1815309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan.
    Watanabe K; Ueno K; Kato N; Muto Y; Bandoh K; Tanaka Y; Jotwani R; Goto M; Shimada K; Shimizu K
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1069-73. PubMed ID: 1295761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.